Seer Bio Partners with Enlight Medical to Commercialize the Proteograph™ Product Suite in China
August 12 2021 - 4:01PM
Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a
disruptive new platform for proteomics, today announced it has
signed an exclusive distribution agreement with Enlight Medical, a
leading company in the development, production and distribution of
innovative medical diagnostics and therapeutic devices in China.
The agreement accelerates commercial availability of Seer’s
Proteograph Product Suite to the rapidly expanding Chinese life
sciences and clinical markets.
China’s life sciences, pharmaceutical and health care markets
are among the largest and the fastest-growing in the world and hold
enormous potential for proteomics. With the surging global health
care needs in oncology, neurology, and immunology, new tools are
needed to accelerate biological insights, identify biomarker
targets, and develop novel therapies. Seer’s unbiased, deep, and
scalable proteomics platform addresses this demand by enabling
pharma and biomedical researchers to discover new biomarkers for
the diagnosis and treatment of cancer and other diseases, and
better understand how healthy cells function.
“We’re experiencing a major shift in how the Chinese population
will receive care, which is driving the demand for more therapies
to treat disease,” said Dr. Ruilin Zhao, CEO of Enlight Medical,
and former China General Manager for Illumina. “Our management team
has decades of industry experience and deep connections with
leading hospitals and universities in China, so we are well
positioned to bring Seer’s Proteograph Product Suite to this
booming market of researchers, clinicians, and doctors to help
Chinese people have longer and healthier lives.”
Through the partnership, Enlight’s experienced team will manage
sales, marketing, and customer service for Seer’s Proteograph
Product Suite and pave the way for expanding access to this
disruptive platform in China. The Proteograph Product Suite, which
leverages Seer’s proprietary engineered nanoparticle technology,
empowers scientists and clinicians to obtain a clearer view of
biology by enabling unbiased, deep access to the proteome at a
scale never before possible.
“We are thrilled to partner with the highly-experienced and
well-respected team at Enlight Medical to accelerate our entry into
the Chinese market,” said Omead Ostadan, President and Chief
Operating Officer at Seer. “China represents a significant
opportunity for us and our partnership with Enlight will allow us
to provide a broad range of customers — spanning academic
institutions, commercial and pharmaceutical companies — access to
the unique capabilities of our platform earlier than we had
originally anticipated. We are excited to embark on this next phase
of our commercial expansion and look forward to serving an
expanding set of global customers in partnership with Enlight
Medical.”
About Seer Bio
Seer is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer is
commercializing its Proteograph Product Suite, an integrated
solution that includes proprietary engineered nanoparticles,
consumables, automation instrumentation and software to perform
deep, unbiased proteomic analysis at scale in a matter of hours.
Seer designed the Proteograph workflow to be efficient and easy to
use, leveraging widely adopted laboratory instrumentation to
provide a decentralized solution that can be incorporated by nearly
any lab. Seer’s Proteograph Product Suite is for research use only
and is not intended for diagnostic procedures. For more
information, please visit www.seer.bio.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on
Seer’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Seer’s actual results, performance, or
achievements to be materially different from those expressed or
implied by the forward-looking statements. These statements include
but are not limited to statements regarding Seer’s ability to
successfully execute the development and commercialization of its
Proteograph; or the combined solution offered by the commercial
agreement, the ability of the combined product offering to enable
labs to perform unbiased, deep proteomics studies at scale to
deliver new levels of insight, speed, and sensitivity, to expand
unbiased proteomics discovery efforts, expand application sets, and
future collaborations. These and other risks are described more
fully in Seer’s filings with the Securities and Exchange Commission
(“SEC”) and other documents that Seer subsequently files with the
SEC from time to time. Except to the extent required by law, Seer
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
About Enlight Medical
Enlight Medical Technologies (Shanghai) Co., Ltd. is committed
to the product development, production, and distribution of
innovative medical diagnostics and therapeutic devices. The
founding team of the company has successful experience and industry
resources in R&D, sales, and marketing. The R&D team is
composed of senior engineers graduated from top universities in
both China and the United States. The company's product pipeline
has a wide layout, covering a variety of innovative products with
huge market potential. The company will always take an
international vision, uphold the heart of benevolence, based in
China, to create a world-class technology provider and product
manufacturer of innovative medical devices.
Seer Media Contact: pr@seer.bio
Enlight Medical Media
Contact:pr@enlight-medical.com
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024